Telisotuzumab vedotin (ABBV-399)

Telisotuzumab vedotin (ABBV-399) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat solid cancer tumors.

Type of Molecule

Biologic

Target

cMet

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Solid Tumors n/a
Phase 1